AACR 2022 | Upcoming trials and novel agents in MPNs
In this video, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, highlights some upcoming clinical trials in myeloproliferative neoplasms (MPNs), including the SURPASS-ET trial (NCT04285086) investigating the use of ropeginterferon alfa-2b for essential thrombocythemia (ET), and novel agents for polycythemia vera (PV), including rusfertide. Dr Mesa also discusses trials in myelofibrosis (MF), including the TRANSFORM trials investigating the use of navitoclax for MF. To conclude, Dr Mesa highlights the promise of these combination trials and the need to further investigate the cumulative benefit of these trials. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
